Consumer Health Products
(Source: Grand View Research, Inc., November 2018)
According to a report published by Grand View Research, Inc., the global acne drug market is expected to reach US$5.9 billion by 2025, registering a 4.2% compound annual growth rate for 2018–2025. Several factors, such as the emergence of biologics, unhealthy lifestyle and rising disease incidence, are expected to drive the market.
Acne is one of the most common dermatological disorders, affecting 9.4% people worldwide.
Although the condition can affect people of all ages, it is most prevalent among teenagers, occurring in more than 85% of people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.
Even though antibiotics play a key role in acne management, increased resistance is a matter of concern. The issue of antibiotic resistance is also affecting prescribing patterns and treatment algorithms.
The standard of care for the treatment of mild-to-moderate acne is topical therapy.
Despite the size of the acne patient population, innovation in acne therapy has remained limited over the past 20 years, mainly involving reformulation of drugs with improved vehicles or development of a combination of approved products.
The acne therapy market is shifting from monotherapy towards combination therapy options. The most likely reason is the higher efficacy of combinations that take into consideration the multifactorial pathogenesis of acne, reduced resistance levels and ease of use of a single product versus separate monotherapies.
Mondias Prevacne complete acne treatment line (cleanser, exfoliant and hydrating cream) has been approved by Health Canada.
The products were created as a three-step concept but can be used individually. Each product contains antibacterial and anti-inflammatory agents to treat and prevent acne.